News
Recent years have seen a 12 percent decline in new HIV infections. Cuts to federal funding could upend that progress.
1d
Rough Draft Atlanta on MSNGLAAD Down South brings Black LGBTQ+ storytellers togetherBlack queer Atlantans gathered at MODEx Studio for GLAAD Down South, an event celebrating LGBTQ+ Southerners, storytellers, ...
If we are going to defeat HIV, we cannot abandon our commitment to fully fund research, and we cannot walk away from our work ...
Gilead Sciences’ long-acting drug to block HIV has the potential to end the AIDS epidemic worldwide. But accessibility ...
Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...
The MoU establishes a framework for collaboration between ADPHC and Gilead Sciences across two core pillars: disease ...
No significant association was observed between viremia history during ART and CVD risk in a large international cohort of patients with HIV infection.
That shows how the company is now overvalued in our view. The largest risk to our thesis is if Gilead Sciences can achieve ...
BofA Securities Health Care Conference May 13, 2025 2:20 PM ET. Company Participants. Johanna Mercier – Chief Commercial Officer. Conference ...
Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where Gilead Sciences, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results